ライフサイエンスコーパス: CVD

1 CVD and CKD event rates by predicted risk group were mul

2 CVD is more prevalent in type 2 diabetes (T2D) than type

3 CVD risk increased with longer stay in Europe.

4 CVD risk was highest in subjects with LBW and HWC (+LBW/

5 CVD was rated as the top concern by only 39% of PCPs, af

6 CVD was rated as the top concern less frequently than we

7 CVD-REAL Nordic was an observational analysis of individ

8 [35 g (1.25 ounces)], and 4) reporting >/=1 CVD risk factor.

9 ber needed to treat (NNT) of 24 to prevent 1 CVD event/death over 5 years (absolute risk reduction [A

10 te cause-specific hazard ratios (HRs) for 12 CVDs, adjusted for cardiovascular risk factors and acute

11 The incidence of 3 CVD risk factors (obesity, sleep complaints, and depress

12 During approximately 7 y of follow-up, 372 CVD deaths and 249 IHD deaths occurred.

13 % uncertainty interval [UI] 141,400-158,500) CVD deaths prevented or postponed (DPPs) by 2030 in the

14 7% for 1 y and prevent approximately 18,600 CVD deaths (95% CI: 17,600, 19,500), gaining approximate

15 ption, corresponding values would be 451,900 CVD deaths prevented or postponed (95% CI: 433,100, 467,

16 We randomly matched 10 controls each to 904 CVD cases based on week of conception.

17 ternal Medicine Cardiovascular Disease (ABIM CVD) Certification Examination is unknown.

18 hird year was a strong predictor of the ABIM CVD score (p < 0.001).

19 f predicted benefit had significant absolute CVD risk reduction, but the overall ACCORD-BP participan

20 fectiveness should be considered, additional CVD risk-reduction measures for adults with SBP/DBP <140

21 possible protective role of this SNP against CVD.

22 social policies and cultural practices alter CVD risk, even in the absence of genetic changes.

23 .83, 95% CI: 0.73, 0.94; Ptrend = 0.002) and CVD (HR = 0.74, 95% CI: 0.61, 0.89; Ptrend = 0.001) mort

24 ion between moderate preterm first birth and CVD was accounted for in part by the development of post

25 <10(-320)) for systolic and diastolic BP and CVD events regardless of the underlying BP genetic risk.

26 ortality, as well as incidence of cancer and CVD, were lower with higher guideline concordance.

27 decreased risk of 6% and 4% of all-cause and CVD mortality, respectively.

28 e independent risk factors for all-cause and CVD mortality.

29 raction (p = 0.329 and p = 0.291 for CKD and CVD, respectively).

30 owledge of any associations between CSHT and CVD.

31 haracterize cardiovascular disease (CVD) and CVD risk factors in transgender populations receiving cr

32 ol concentrations within a saturated fat and CVD context].

33 on presidential advisory on dietary fats and CVD reviews and discusses the scientific evidence, inclu

34 e association between LC n-3 PUFA intake and CVD risk.We determined whether a PCSK9 variant (rs112065

35 sease, Coronary Disease & Interventions, and CVD Prevention & Health Promotion (1-74).

36 er adjustment for prepregnancy lifestyle and CVD risk factors.

37 afford a new strategy for lipid-lowering and CVD risk reduction.

38 rcise, nutrition, and weight management) and CVD risk factor (blood pressure, cholesterol and blood l

39 vity are associated with lower mortality and CVD in countries at different economic levels.

40 d cheese, may reduce the risk of overall and CVD mortality.

41 netic variant of IL-32 on lipid profiles and CVD risk was therefore studied in whole blood from indiv

42 .69) and 0.89 (0.87-0.91), respectively; and CVD death, HR 0.64 (0.59-0.70), and 0.85 (0.81-0.90), re

43 y controlling temperature, pattern size, and CVD duration, optimal conditions were determined by char

44 incident coronary heart disease, stroke, and CVD associated with a 1-SD decrease in mtDNA-CN were 1.2

45 myocardial infarction, nonfatal stroke, and CVD mortality.

46 e was no association between alcohol use and CVD risk factors (diabetes, hypertension, hyperlipidemia

47 delivered an infant preterm (<37 weeks) and CVD in 70 182 parous women in the Nurses' Health Study I

48 0477) felt extremely well prepared to assess CVD risk in women, while 42% and 40% felt well-prepared

49 e contribute significantly to age-associated CVD-related morbimortality.

50 adults who are at increased atherosclerotic CVD risk and may be considered for statins.

51 KD have substantially greater risks for both CVD and CKD events compared with those at low predicted

52 that people at high predicted risk for both CVD and CKD have substantially greater risks for both CV

53 D:A:D at high (>5%) predicted risk for both CVD and CKD would be at even greater risk for CVD and CK

54 We calculated CVD and CKD event rates by predicted 5-year CVD and CKD

55 y and incident coronary heart disease (CHD), CVD, and cancer over a mean 8.9 (standard deviation, 3.5

56 k factor profiles, and were free of clinical CVD, were included in this study.

57 -technology ways to quantify and communicate CVD risk at population or individual levels.

58 PHA may offer a useful avenue to communicate CVD risk.

59 d with cardiovascular outcomes (HR composite CVD 0.92, 95% CI, 0.89-0.94).

60 Adverse events comprised CVD death, myocardial infarction, coronary insufficiency

61 Outcomes included cumulative CVD (coronary heart disease and stroke) deaths prevented

62 livering babies with cardiovascular defects (CVDs).

63 Congenital colour vision deficiency (CVD), commonly called 'colour blindness', affects around

64 Choroidal vascular density (CVD) was calculated as a percent area occupied by choroi

65 ) synthesized by chemical vapor deposition (CVD) are studied using a local probe method enabled by s

66 g basal planes by chemical vapor deposition (CVD) is demonstrated.

67 ilm by a two-step chemical vapor deposition (CVD) method followed by a laser thinning process.

68 wth of MoS2 using chemical vapor deposition (CVD) on non-birefringent thermal oxide on a silicon wafe

69 GNR) formation by chemical vapor deposition (CVD) on top of Au(111) surfaces.

70 rated the use of chemical vapour deposition (CVD) grown-graphene to develop a highly-ordered graphene

71 the traditional chemical vapour deposition (CVD) production for NPs from mg level to 10 s of grams p

72 refore, it is important to be able to detect CVD biomarkers early so that patients can be diagnosed p

73 h sensitivity for PoC applications to detect CVD biomarkers such as S100 beta proteins and C-reactive

74 culminating in increased risk of developing CVD.

75 accounted for differences in baseline diets, CVD rates, MMC coverage, MMC duration, and declining eff

76 14 cases of incident cardiovascular disease (CVD) (myocardial infarction, unstable angina, arterial r

77 creased incidence of cardiovascular disease (CVD) among individuals with low vitamin D status.

78 arch to characterize cardiovascular disease (CVD) and CVD risk factors in transgender populations rec

79 ership with incident cardiovascular disease (CVD) and death in a register-based prospective nation-wi

80 red meat intake and cardiovascular disease (CVD) are inconsistent.

81 xplains the reported cardiovascular disease (CVD) benefits of intensive BP lowering in this populatio

82 available comparing cardiovascular disease (CVD) biomarker profiles between women and men in the gen

83 optimally determine cardiovascular disease (CVD) by middle age.

84 Cardiovascular disease (CVD) complications are important causes of morbidity and

85 in sodium intake and cardiovascular disease (CVD) context and low density lipoprotein-cholesterol con

86 treatment can avert cardiovascular disease (CVD) events but can cause some serious adverse events.

87 retinopathy (DR) and cardiovascular disease (CVD) focused on the early stages of DR.

88 are at high risk of cardiovascular disease (CVD) in part owing to hypertriglyceridemia and low high-

89 attern influences on cardiovascular disease (CVD) incidence and mortality during the intervention and

90 Cardiovascular disease (CVD) is an increasing cause of morbidity among persons l

91 Cardiovascular disease (CVD) is the number 1 killer of women in the United State

92 or 2) with total and cardiovascular disease (CVD) mortality and incident coronary heart disease (CHD)

93 tes on all-cause and cardiovascular disease (CVD) mortality or if diabetes serves as a mediator in th

94 tation of risk-based cardiovascular disease (CVD) prevention requires risk prediction tools that are

95 ety in patients with cardiovascular disease (CVD) remain unclear.

96 ment might influence cardiovascular disease (CVD) risk are still a matter of debate.

97 rt disease (IHD) and cardiovascular disease (CVD) risk factors are inconsistent, probably because of

98 aran Africa, adverse cardiovascular disease (CVD) risk factors have been observed to be higher than f

99 surements to predict cardiovascular disease (CVD) risk has not been rigorously assessed.

100 Using cardiovascular disease (CVD) risk instead of or in addition to blood pressure (B

101 portant influence on cardiovascular disease (CVD) risk, progression, and severity.

102 eir association with cardiovascular disease (CVD) were limited by small numbers of patients or a narr

103 tors and subclinical cardiovascular disease (CVD) with the hypothesis that people living in FD will h

104 cular complications, cardiovascular disease (CVD), and cancer progression and metastasis.

105 th increased risk of cardiovascular disease (CVD), but it is unknown whether this risk remains after

106 , a major problem in cardiovascular disease (CVD), contributes yearly to approximately 125,000 preven

107 main risk factor for cardiovascular disease (CVD), is becoming progressively more prevalent in our so

108 ircumference (WC) on cardiovascular disease (CVD).

109 iated with premature cardiovascular disease (CVD).

110 fatty acid (SFA), on cardiovascular disease (CVD).

111 tion of MGO prevents cardiovascular disease (CVD).

112 tially free of overt cardiovascular disease (CVD).

113 n diet (MedDiet) and cardiovascular disease (CVD).We evaluated the associations between 1) lipid spec

114 n to protect against cardiovascular disease (CVD).We investigated the associations between hydroxytyr

115 rt disease (CHD) and cardiovascular disease (CVD); however, prognostic data on CAC are limited in you

116 creases the risk of Cardio-vascular disease (CVD).

117 1,637 men died from cardiovascular diseases (CVD), 2,122 from cancer during a median of 9.29 years' f

118 emiological data on cardiovascular diseases (CVD), its risk factors, and describe strategies aimed at

119 reduce the risk of cardiovascular diseases (CVDs).

120 for and outcome of cardiovascular diseases (CVDs).

121 Cardiovascular and cerebrovascular diseases (CVDs) related to overwork are common in Asia, as is deat

122 However, reliable data to estimate CVD burden are lacking in many regions of the world, whi

123 rdiac troponin concentration with first-ever CVD outcomes (i.e., coronary heart disease [CHD], stroke

124 Participants with pre-existing CVD were excluded from the analyses.

125 CVD (IRR, 1.39; 95% CI, 1.16-1.67) and fatal CVD (IRR, 2.33; 95% CI, 1.49-3.67) compared with those w

126 For fatal CVD, associations were stronger in North American studie

127 ating catalyst chemical vapor deposition (FC-CVD) process permits macro-scale assembly of nanoscale m

128 ause mortality, 3.15 (95%CI: 2.44, 4.05) for CVD mortality, and 3.18 (95%CI: 2.55, 3.97) for cancer m

129 Associations persisted after adjustment for CVD risk factors, joint pain, rheumatoid factor positivi

130 ruption is emerging as a new risk factor for CVD.

131 significant differences in risk factors for CVD or markers of subclinical CVD.

132 lts with T2D meet recommended guidelines for CVD prevention.

133 HRs for CVD mortality and IHD mortality for theoretical, isocalo

134 VD and CKD would be at even greater risk for CVD and CKD events.

135 risk score can identify patients at risk for CVD complications after OLT surgery (available at www.ca

136 with SBP/DBP <140/90 mm Hg at high risk for CVD may be warranted.

137 r impairments in this population at risk for CVD such as stroke or WMHs.

138 dent predictors of a higher 10-year risk for CVD.

139 Participants were followed-up for CVD mortality after linkage to national mortality regist

140 ntly predictive of CVD and may be useful for CVD prevention efforts.

141 ng the follow-up, 556 participants died from CVD.

142 llas Heart Study (n=2202) who were free from CVD and underwent measurement of left ventricular hypert

143 ncluding 21870 participants (20163 free from CVD at baseline) from 3 studies: Cardiovascular Health S

144 parison with men but were not protected from CVD events.

145 llow-up, 8.2% of the women had suffered from CVD, 4.9% had suffered from coronary heart disease, and

146 Data were from CVD-free adults in World Health Organization Study on Gl

147 uations with estimates >/=7.5% defining high CVD risk.

148 lain why participants from Russia had higher CVD mortality when compared to participants from Poland/

149 e control arm presented significantly higher CVD risk.

150 primary outcome measures were evaluated: (i) CVD events/deaths (myocardial infarction, acute coronary

151 on or other management strategies to improve CVD outcomes after OLT.

152 have potential clinical utility in improving CVD risk classification.

153 eduction (56,100; 95% CI: 52,400, 57,700) in CVD deaths.

154 CCORD-BP who had lower versus higher ARRs in CVD events/deaths with intensive BP treatment, and parti

155 nge (APC) and evaluated whether decreases in CVD mortality accelerated after 2002 in either NYC or th

156 Significant differences in CVD mortality rates and changes over time were found amo

157 tensive treatment, the broad distribution in CVD risk for people with similar BP levels, and the use

158 fication of Hispanics masks heterogeneity in CVD mortality reporting, leading to an incomplete unders

159 5.0; 95% CI, 2.8-8.7) and 3-fold increase in CVD events (HR, 3.0; 95% CI, 1.9-4.7).

160 we estimated and compared the reductions in CVD mortality and socio-economic disparities in the US p

161 harmacotherapies and behavioral therapies in CVD patients.

162 Incident CVD included CHD, stroke, heart failure, and peripheral

163 Incident CVD, which combines coronary heart disease, defined as t

164 with 57 incident CHD events and 108 incident CVD events observed.

165 years (range, 3.2-10.1 years), 1203 incident CVD events, including 916 coronary heart disease cases,

166 between baseline ceramide score and incident CVD varied significantly by treatment groups (Pinteracti

167 models, associations between CA and incident CVD were seen in men (1.73 [1.12-2.67]) and not in women

168 ssociations between baseline CA and incident CVD, adjusting for traditional CVD risk factors includin

169 between HDL-related biomarkers and incident CVD.

170 follow-up visits, and well-defined incident CVD end point.

171 of 7.7 years, 2584 participants had incident CVD events.

172 DME or PDR were more likely to have incident CVD (IRR, 1.39; 95% CI, 1.16-1.67) and fatal CVD (IRR, 2

173 Main Outcome and Measures: Incident CVD, including coronary heart disease, stroke, or death

174 ted with total, fatal, and nonfatal incident CVD (hazard ratios [HRs] 1.47 [95% CI 1.13-1.91], 1.42 [

175 ME or PDR have an increased risk of incident CVD, which suggests that these persons should be followe

176 The main outcome was self-reported incident CVD, defined as new myocardial infarction, angina pector

177 The primary outcome was incident CVD, defined by the first occurrence of fatal or nonfata

178 A was independently associated with incident CVD (odds ratio [95% confidence interval]: 1.52 [1.07-2.

179 was the number of participants with incident CVD and death, including a prespecified subgroup analysi

180 and compare their associations with incident CVD and to obtain a system-level understanding of the co

181 N was independently associated with incident CVD in 3 large prospective studies and may have potentia

182 ere stages of DR (DME and PDR) with incident CVD in patients with type 2 diabetes.

183 asma MGO levels are associated with incident CVD in people with type 1 diabetes is unknown.

184 most significantly associated with incident CVD were apoC-II (hazard ratio per 1 SD [HR/SD]: 1.40; 9

185 ht <2500 g were at a significantly increased CVD risk when compared to subjects with birth weight bet

186 economic and cultural factors that influence CVD risk factors may be necessary to prevent CVD in LMIC

187 vice fabrication, with emphasis on initiated CVD (iCVD) and oxidative CVD (oCVD) polymerization.

188 31 participants who remained free of interim CVD events; of these, 1723 received gadolinium-enhanced

189 Lifetime CVD risk was 64.8% for HIV-infected males compared to 54

190 urated fatty acids are associated with lower CVD risk, although the effects of fish oil supplementati

191 ciated, as a continuous variable, with lower CVD risk, but only HVAL showed a strong inverse associat

192 5, 0.60-0.71; p<0.0001 for trend), and major CVD (0.86, 0.78-0.93; p<0.001 for trend).

193 Among 1,024 first OLT recipients, major CVD complications occurred in 329 (32.1%).

194 report discusses the mechanisms of the major CVD polymerization techniques and the recent progress of

195 Campaigns should make CVD "real" to U.S. women, countering stereotypes with fa

196 ificant associations were observed with mean CVD.

197 e reductive alkylation reaction in monolayer CVD graphene films.

198 re are significant disparities in control of CVD risk factors by sex, socioeconomic status, and level

199 for each country and make the estimation of CVD risk possible without using laboratory-based measure

200 7 men and women aged 43-74 years and free of CVD at baseline examination during 2002-2005.

201 artly attributable to only about one-half of CVD patients consistently taking prescribed life-saving

202 d at least 1 later preterm birth had a HR of CVD of 1.65 (95% CI, 1.20-2.28).

203 nsaturated fats, will lower the incidence of CVD.

204 CA is an additional observable indicator of CVD in men.

205 ular risk factors and preclinical indices of CVD, these associations are mainly driven by area income

206 ic uremia- and PD-induced pathomechanisms of CVD.

207 term delivery is independently predictive of CVD and may be useful for CVD prevention efforts.

208 of aspirin) management for the prevention of CVD among patients with T2D.

209 behavioral counseling for the prevention of CVD in this population.

210 ntial target for blocking the progression of CVD.

211 The exceptional properties of CVD graphene were exploited to construct a highly sensit

212 ronment affects the electrical properties of CVD-grown monolayer MoS2 by monitoring electrical parame

213 al response and the electronic properties of CVD-grown structures.

214 The increased rate of CVD in the very preterm group persisted even among women

215 sugars is not associated with lower rates of CVD and did not reduce CVD in clinical trials.

216 urated fat is associated with lower rates of CVD and of other major causes of death and all-cause mor

217 sociated with a significantly higher risk of CVD (hazard ratio, 1.46; 95% confidence interval, 1.14-1

218 ons between 1) lipid species and the risk of CVD (myocardial infarction, stroke, or cardiovascular de

219 s associated with a 2.18-fold higher risk of CVD across extreme quartiles (HR, 2.18; 95% CI, 1.36-3.4

220 ated or decaffeinated, may lower the risk of CVD and IHD mortality in patients with a prior MI.

221 n +/- SD age of 66.8 +/- 6 y at high risk of CVD from prospective cohort data.

222 terdam, Berlin, and London), 10-year risk of CVD was estimated using the Pooled Cohort Equations with

223 ly and inversely associated with the risk of CVD.

224 dy and relate their plasma levels to risk of CVD.

225 odeling yielded significantly lower risks of CVD mortality when replacing SFAs plus TFAs with total U

226 ir therapeutic potential in the treatment of CVD.

227 eople with similar BP levels, and the use of CVD risk for guiding antihypertensive treatment among su

228 by other types of fats and carbohydrates on CVD.

229 f elevated plasma ceramide concentrations on CVD.

230 adverse BP genetic profile and its effect on CVD risk.

231 ietary fatty acids have divergent effects on CVD risk, and the effects also depend strongly on the co

232 to determine the association of migration on CVD risk.

233 tive impact of different dietary policies on CVD disparities is not well established.

234 markers on the effect of multivitamin use on CVD and other outcomes.

235 red to those at high predicted risk for only CVD or CKD events.

236 type 2 diabetes and either prevalent CVD or CVD risk factors and high-density lipoprotein levels les

237 ndrome, stroke, congestive heart failure, or CVD death), and (ii) serious adverse events (hypotension

238 .8 for CHF (P = 0.01), and 497.2 for overall CVD (P < 0.001).

239 phasis on initiated CVD (iCVD) and oxidative CVD (oCVD) polymerization.

240 Participants' CVD and CKD risk groups had multiplicative predictive ef

241 ther published risk models for postoperative CVD morbidity and mortality, and it had appropriate cali

242 Children are devoid of preexisting CVD and provide unique insight into specific uremia- and

243 ; 95% CI, 4.0-41.1), as was the very-preterm-CVD relationship (13.1%; 95% CI, 9.0-18.7).

244 ence of type 2 diabetes and either prevalent CVD or CVD risk factors and high-density lipoprotein lev

245 e vitamin D supplementation does not prevent CVD.

246 CVD risk factors may be necessary to prevent CVD in LMICs.

247 hould be followed up more closely to prevent CVD.

248 MC would be 35% less effective in preventing CVD deaths in non-Hispanic blacks than in whites.

249 Participants without prior CVD had an intervention period CHD HR of 0.70 (95% CI: 0

250 e levels of 400 mg/dL or less, without prior CVD.

251 ts the need to understand how aging promotes CVD in order to develop new strategies to confront this

252 suggests that fenofibrate therapy may reduce CVD in patients with diabetes with hypertriglyceridemia

253 d with lower rates of CVD and did not reduce CVD in clinical trials.

254 economic policies would significantly reduce CVD socio-economic disparities.

255 could improve adherence, and thereby reduce CVD death and disability.

256 old increase in the rate of overwork-related CVDs (p-value < 0.05).

257 itudinal change in rates of overwork-related CVDs before and after, adjusting for indicators of worki

258 ce criteria for recognizing overwork-related CVDs in 1961.

259 nd physicians endorsed investment in women's CVD research and physician education.

260 od as a rapid, inexpensive, high sensitivity CVD biomarker assay.

261 ntervention arms of the trial showed similar CVD risk to those with a lower ceramide score, whereas p

262 s the stage for the use of acetylene-sourced CVD-grown graphene as a fundamental building block in th

263 ncluded myocardial infarction, total stroke, CVD mortality, and total mortality individually.

264 Progression of subclinical CVD was defined by 10-year change in left ventricular st

265 sk factors for CVD or markers of subclinical CVD.

266 hypertension, hyperlipidemia) or subclinical CVD measures (coronary artery calcification, early trans

267 1-y changes in lipid species and subsequent CVD.With the use of a case-cohort design, we profiled 20

268 By employing low processing temperatures, CVD polymerization avoids damaging substrates and underl

269 The CVD method is particularly suitable for synthesizing ins

270 rise an increasingly large proportion of the CVD population.

271 These CVD-grown ML MoS2 flakes exhibit much higher mobility an

272 meat/d would have a negative effect on these CVD risk factors.

273 th systems, health policies, and barriers to CVD prevention and care).

274 ties for women and physicians with regard to CVD.

275 hat multiple factors are causally related to CVD, including traditional individual level risk factors

276 ions with biomarkers potentially relevant to CVD pathogenesis and inflammation, and evidence of a hig

277 y and compare the potential effects on total CVD mortality and disparities of specific dietary polici

278 s (PARs) were 0.41, 0.40 and 0.38 for total, CVD and cancer mortality, accordingly.

279 he built environment and progression towards CVD.

280 and incident CVD, adjusting for traditional CVD risk factors including age, sex, serum cholesterol,

281 After controlling for traditional CVD risk factors, CA was independently associated with i

282 ression adjusting for age, race, traditional CVD risk factors, kidney function, insulin resistance, M

283 people living in FD will have an unfavorable CVD risk profile.

284 and price-reduction policies could reduce US CVD mortality, with price reduction being more powerful

285 e also review population-level data on using CVD risk in conjunction with BP to guide antihypertensiv

286 -degradable polymer directly synthesized via CVD.

287 and fitted Poisson models to assess whether CVD and CKD risk group effects were multiplicative.

288 ee consumption was inversely associated with CVD mortality, with HRs of 0.69 (95% CI: 0.54, 0.89) for

289 1.05; 95% CI, 0.88-1.26) was associated with CVD risk in blacks, whereas DBP (HR, 1.74; 95% CI, 1.21-

290 0.82; 95% CI, 0.57-1.18) was associated with CVD risk in whites.

291 ather than food access, were associated with CVD risk measures.

292 comes, intermediate outcomes associated with CVD, or dietary or physical activity behaviors in adults

293 of some lipids were directly associated with CVD.

294 esters (CEs) were inversely associated with CVD.

295 o known as homovanillyl alcohol (HVAL), with CVD and total mortality.We included 1851 men and women w

296 After excluding participants with CVD, the study population included 3439 individuals, mea

297 The proportion with CVD risk >/=7.5% among Ghanaian men was 34.7% in rural G

298 iency is achieved in the PEI sandwiched with CVD-grown h-BN films at elevated temperatures when compa

299 associated with the potential for worsening CVD risk factors (such as blood pressure elevation, insu

300 CVD and CKD event rates by predicted 5-year CVD and CKD risk groups (</=1%, >1%-5%, >5%) and fitted